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Paranoia is receiving increasing attention in its own right, 
since it is a central experience of psychotic disorders and 
a marker of the health of a society. Paranoia is associated 
with use of the most commonly taken illicit drug, cannabis. 
The objective was to determine whether the principal psy-
choactive ingredient of cannabis—∆9-tetrahydrocannabinol 
(THC)—causes paranoia and to use the drug as a probe 
to identify key cognitive mechanisms underlying paranoia. 
A  randomized, placebo-controlled, between-groups test of 
the effects of intravenous THC was conducted. A total of 
121 individuals with paranoid ideation were randomized 
to receive placebo, THC, or THC preceded by a cognitive 
awareness condition. Paranoia was assessed extensively via 
a real social situation, an immersive virtual reality experi-
ment, and standard self-report and interviewer measures. 
Putative causal factors were assessed. Principal compo-
nents analysis was used to create a composite paranoia 
score and composite causal variables to be tested in a medi-
ation analysis. THC significantly increased paranoia, nega-
tive affect (anxiety, worry, depression, negative thoughts 
about the self), and a range of anomalous experiences, and 
reduced working memory capacity. The increase in negative 
affect and in anomalous experiences fully accounted for the 
increase in paranoia. Working memory changes did not lead 
to paranoia. Making participants aware of the effects of 
THC had little impact. In this largest study of intravenous 
THC, it was definitively demonstrated that the drug triggers 
paranoid thoughts in vulnerable individuals. The most likely 
mechanism of action causing paranoia was the generation 
of negative affect and anomalous experiences.
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Introduction
Paranoia—unfounded fears that others intend harm to the 
individual—is a central experience of psychotic disorders 
such as schizophrenia. Factor analytic studies indicate that 
it is an independent experience that requires explanation 
in its own right.1 Many people have a few paranoid ideas, 
and a few people have many.2 Paranoia is associated with 
youth, poverty, poor physical health, suicidal ideation, 
and the use of cannabis.3 We took this latter association 
to carry out a unique experimental investigation into the 
causes of paranoia. First, we set out to establish that can-
nabis causes paranoia, using the most comprehensive bat-
tery ever used to assess such fears. Second, cannabis was 
used as a probe to identify the key cognitive mechanisms 
causing paranoid fears. Determination of the immediate 
causes can be used to advance the treatment of delusions.4
A Cognitive Account of Paranoia
Our cognitive account of paranoia identifies multiple 
causes (see figure 1).5 It is hypothesized that the individual 
experiences an anomalous internal state. These anomalies 
may include, across the different senses, changes in sensory 
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intensity, distorted sensory experience, sensory flooding, 
unusual sensory experience, thought echo, and hallucina-
tions.6 They may also include feelings of unusual salience.7 
The anomalies may be triggered by, eg, life events, poor 
sleep, or illicit drugs such as cannabis. In essence, the person 
feels different and this requires an explanation. Odd experi-
ences encourage unusual thoughts. Importantly, a negative 
affective state makes a paranoid interpretation likely: anxi-
ety leads to the threat content; negative self beliefs high-
light the person’s vulnerability to harm; and engagement in 
worry results in negative, implausible ideas. The fears reach 
a delusional level of conviction when reasoning biases, such 
as jumping to conclusions, are present. Working memory 
performance moderates the effect of the reasoning biases.8,9
Using ∆9-Tetrahydrocannabinol to Determine the 
Causes of Paranoia
Establishment of causal roles requires manipulation of 
the factors of interest.10 We saw the administration of 
cannabis as a method of manipulating key putative causal 
factors in paranoia, while also providing an important 
opportunity to learn about a substance seen by many as a 
contributory cause of psychosis (eg, Casadio et al11).
The principal psychoactive constituent of cannabis 
is ∆9-tetrahydrocannabinol (THC). THC administered 
intravenously is characterized by the appearance of 
psychopharmocological effects within 5 minutes, which 
continue for at least 90 minutes, providing an excellent 
experimental window.12 In within-subjects tests with non-
clinical volunteers, D’Souza, in particular, has shown 
that intravenous administration of THC causes schizo-
phrenia-like symptoms, perceptual disturbances, anxiety, 
and impaired working memory (eg, Morrison et al13 and 
D’Souza et al14,15). Similar but more pronounced results 
were found in patients with schizophrenia.15
Principally, the psychosis-inducing effects of canna-
bis have been linked to an abnormal salience theory,16,17 
in which THC leads to an increase in anomalous expe-
rience which is then misinterpreted. However, THC can 
TRIGGER
Major life events, on-going stress, sleep 
disturbance, trauma, illicit drugs. 
EMOTION 
Anxiety, worry, negative 
beliefs about the self, others 
and the world formed in up-
bringing and subsequent 
experiences. 
REASONING
Jumping to conclusions, 
confirmation bias, failure to 
consider alternatives. 
INTERNAL AND EXTERNAL 
EVENTS 
Internal: arousal, anomalous 
experiences, core cognitive dysfunction 
External: Discrepant, negative, socially 
significant, or ambiguous events.
SEARCH FOR MEANING 
Search for understanding/meaning
Not wanting to talk to others/having
nobody to provide feedback on ideas.  
THE PERSECUTORY 
(THREAT) BELIEF 
Fig. 1. Outline of factors involved in persecutory delusion development.5
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also induce anxiety via cannabinoid receptors in the 
amygdala.18 Therefore, the prediction from the cognitive 
model of paranoia is that THC leads to such fears via 
2 routes: the generation of confusing anomalous experi-
ences and an increase in negative affect and related pro-
cesses. Working memory is clearly affected by THC, but 
since such cognitive problems have not been linked to the 
positive symptoms of psychosis,19 a direct memory per-
formance route to paranoia would not be expected.
The Current Study
In the current study, we set out to identify the causes of 
paranoia via the administration of THC. This requires 
a between-groups test of the administration of THC 
against placebo. A third condition tested a further causal 
factor: misinterpretation. The cognitive perspective con-
siders paranoia to be a misinterpretation of events. If  
individuals are made sufficiently aware of the potential 
subjective effects of THC, then this may alter the inter-
pretation made and hence the occurrence of paranoia. 
Therefore, the third condition was a cognitive awareness 
manipulation in which the potential effects of THC were 
explained before drug administration. The participants 
to be tested were selected from the general population on 
the key criterion of having had recent paranoid ideation. 
This was therefore an analogue population, in order that 
the results are applicable to understanding the clinical 
phenomenon; testing individuals without signs of vulner-
ability to disorder would be much less informative about 
clinical paranoia, while testing patients in such large 
numbers would have ethical and practical difficulties. We 
were mindful of “the paranoia problem,” the difficulty of 
determining whether persecutory ideation is unfounded, 
so the battery of tests included the most extensive range 
of paranoia assessments yet used in a study. There were 
3 hypotheses: (a) THC increases the occurrence of para-
noia, (b) the occurrence of anomalous experiences and 
negative affect (but not alterations in working memory) 
explains (ie, mediates) the increase in paranoia, and (c) 
that paranoid interpretations can be partially blocked 
by cognitive awareness. The second hypothesis concern-
ing underling mechanisms is the hardest to establish—we 
note the advice of Bullock and colleagues20 “to think of 
mediation analysis as a cumulative enterprise.”
Methods
Participants
There were 121 participants. The inclusion criteria were: 
aged between 21 and 50, had taken cannabis at least once 
before, and reported a paranoid thought in the past month 
as assessed by the Paranoid Thoughts Scale Part B.21 The 
exclusion criteria were: a history of mental illness or sub-
stance dependence, a history of major mental illness in 
a first-degree family member, a neurological condition, 
a heart condition, a history of fainting, photo-sensitive 
epilepsy, or being a pregnant or nursing mother. The 
inclusion criteria concerning age and previous use of can-
nabis, as well as all the exclusion criteria, were designed 
to minimize the chances of any significant adverse effects. 
The psychiatrists carrying out the administration of the 
vials also carried out a brief  health check. The study had 
received approval from an NHS research ethics commit-
tee, and written informed consent was received from all 
participants. Participants were recruited via distribution 
of leaflets to local postcodes and the playing of local 
radio adverts in Oxfordshire, UK.22 The study was also 
advertised at a number of colleges in the University of 
Oxford, at Oxford Brookes University, and on the website 
of a local newspaper. The adverts did not mention canna-
bis or paranoia. The wording was: “Volunteers Required 
for Psychological Research. We are looking for volunteers 
to take part in a medical research study being carried out 
at the university. The research would take three hours and 
you would be compensated for your time. If  you would 
like to hear more about the research, then please contact 
us. We send detailed information about the study so that 
you can consider whether you would like to take part.” 
The individuals who responded were then invited to take 
part in the screening stage. Depending on participant 
preference, the screening questionnaires were either com-
pleted online via a web-link or sent via post. Therefore, 
screening was self-report. A total of 1792 people were 
screened. The reasons for exclusion (which could be sev-
eral for a person) were: outside the age range (n = 611), 
had not taken cannabis before (n = 1117), did not report 
persecutory ideation (n = 739), had a history of mental 
illness (n = 281), substance abuse (n = 41), or major men-
tal illness in a first-degree family member (n = 100), had a 
neurological condition (n = 37), had a history of fainting 
(n = 53), had a heart condition (n = 83), had photo-sen-
sitive epilepsy (n = 2), were pregnant or a nursing mother 
(n = 17), had other physical health problems (n = 5), or 
had high blood pressure prior to administration of the 
vial (n = 5). Totally, 106 people were suitable but declined 
to take part or were not contactable.
Design
The study was a between-groups design. After assessment 
on the cognitive variables, participants were randomized 
to either placebo, THC, or THC with cognitive aware-
ness. Randomization was carried out by a researcher 
independent of recruitment and testing, using random-
ized permuted blocks of varying size with a plan created 
from www.randomization.com. Participants, assessors, 
and the psychiatrists were blind to the placebo and THC 
conditions. For the cognitive awareness condition, both 
participant and assessor were aware the participant 
was to receive THC. After administration of the con-
tents of the vials, participants completed the paranoia 
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assessments and repeated the cognitive tests. Testing on 
all measures postadministration was complete in an aver-
age of 83 minutes (SD = 18). There was a debriefing at the 
end of testing. A taxi was provided for returning partici-
pants home at the end. Participants were contacted the 
following day to check for any adverse effects.
Randomization Conditions
THC (Dronabinol) was supplied by THC Pharm GmbH 
and prepared as vials for injection by Bichsel Laboratories 
according to the method of Naef and colleagues.23 The 
THC had 99.5% purity. A  1.5 mg dose of THC was 
used. Vials of the placebo and THC were indistinguish-
able. A psychiatrist administered either placebo (10 ml of 
saline) or synthetic THC (1.5 ml of THC diluted in saline 
to 10 ml volume). The solutions were administered via an 
indwelling forearm cannula in 1 ml pulses every 1 minute 
for 10 minutes. Blood pressure was monitored during this 
period, and the psychiatrist was always available during 
the testing. Lorazepam (oral, 1–2 mg) was available in 
case a person became significantly distressed but this was 
not used during the study.
The cognitive awareness condition, given before THC 
administration, involved a simple 5-minute educational 
module, explaining the range of effects that the drug can 
cause (THC was considered synonymous with cannabis 
for this procedure). From before to after the awareness 
training, ratings on 2 visual analogue scales significantly 
increased; these assessed the participants’ potential attri-
bution of effects (“After being given the cannabis, how 
much do you believe that if  you have any good or bad 
feelings over the next 90 minutes that cannabis will be the 
cause?”), t(40) = −6.59, P < .001, and confidence to keep 
this in mind (“If you feel different after being given can-
nabis, how easy will it be to keep in your mind that the 
cannabis is the cause?”), t(40) = −5.11, P < .001.
Assessments
The National Statistics Socioeconomic Classification 
analytic classes were used.24 History of illicit drug use 
was collected using the Maudsley Addiction Profile.25 
Intellectual functioning was estimated using the Wechsler 
Abbreviated Scale of Intelligence.26
Paranoia was assessed in 4 ways. A total score (Paranoid 
VAS) was obtained from 6 visual analogue scales (“Right 
now I feel suspicious of other people,” “Right now I feel 
that people want to harm me,” “Right now I feel like peo-
ple want to upset me,” “Right now I feel like people are 
against me,” “Right now I  am thinking that others are 
trying to persecute me,” and “Right now I feel like peo-
ple are being hostile towards me”) (Cronbach’s α = .90), 
which were used at baseline, after administration of the 
vial contents, and at the end of testing. Immediately 
after vial administration, participants were escorted on a 
5-minute walk to the virtual reality testing room. On the 
way, they were asked to go into the hospital canteen and 
purchase an item. After doing this, they completed the 6 
paranoia visual analogue scales in relation to the people 
encountered on the walk (Social Situation Paranoia). 
They then completed 5 minutes in an immersive virtual 
reality social environment (see supplementary figure 1). 
The virtual underground was displayed using an NVIS 
SX111 head mounted display (as used in Freeman et al27). 
Because the environment is neutral, any perceived hostil-
ity is known to be unfounded. Participants’ views of the 
computer characters were assessed using the State Social 
Paranoia Scale (SSPS)28 and a visual analogue scale 
(“Please mark on the line how hostile you thought the 
people on the tube were”) (VAS VR Hostile). Participants 
were also assessed by an interviewer on the suspicious-
ness item of the Positive and Negative Symptom Scale 
(PANSS Suspiciousness).29 The Community Assessment 
of Psychic Experiences (CAPE)30 was included, com-
pleted for the time period since vial administration.
The following putative mediation variables were assessed: 
anomalous experiences using the Cardiff Anomalous 
Perceptions Scale (CAPS)6; anxiety using the Beck Anxiety 
Inventory31; visual analogue scales for anxiety (“how anx-
ious you feel right now”), depression (“how miserable or 
sad you feel right now”), worry (“how worried you feel 
right now”), and self-focus (“Right now my attention is 
focused on my inner thoughts and feelings,” “Right now my 
attention is focused on how I appear to others,” “Right now 
my attention is focused on my surroundings”); catastroph-
izing32; interpersonal sensitivity33; negative and positive 
views of the self and others using the Brief Core Schema 
Scales34; threat anticipation35; jumping to conclusions36; 
belief flexibility assessed by responses indicating that there 
is a possibility that participants could be mistaken in 3 high 
conviction beliefs; and working memory assessed by the 
digit span and letter-number subtests of the WAIS III.37 
Questionnaires were adapted for state use as appropriate.
Statistical Analysis
All analyses were carried out using Stata38 and SPSS.39 The 
analyses involved data reduction (simplification) using 
principal components analyses (PCA), our aim being to 
generate orthogonal (uncorrelated) composite measures 
to eliminate the problems of colinearity. No attempt was 
made to fit a formal measurement model (eg, via confir-
matory factor analysis), the latter being both unnecessary 
and inappropriate for an exploratory analysis of the pres-
ent type. Instead of doing multiple analyses of the para-
noia outcomes, a PCA was undertaken (on the correlation 
matrix) for all 6 measures together (Paranoid VAS post 
THC administration, Paranoid VAS at end of testing, 
Social Situation Paranoia, SSPS, VAS VR Hostile, and 
PANSS Suspiciousness) and the first principal component 
(representing 71% of the total variation) was used as the 
primary outcome in all future analyses. This component 
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was scaled to have a mean (for the whole sample) of 0 and 
a SD of 1 (note that the scaling is arbitrary and has no 
effect on the findings). The following weights were used 
to calculate this first principal component from the above 
6 standardized paranoia assessments, respectively: 0.433, 
0.428, 0.350, 0.417, 0.41, and 0.398. Principal component 
scores were available for 119 participants.
Two binary dummy variables were then created: THC 
= 0 for placebo, =1 for THC or THC + Cognitive aware-
ness; Cognitive Awareness  =  0 for placebo or THC, =1 
for THC+ Cognitive Awareness. When both are entered 
together as explanatory variables in a regression model, 
then the parameter corresponding to THC is the estimate of 
receiving THC and the parameter for Cognitive Awareness 
is the effect of the cognitive awareness condition on those 
receiving THC. Intention-to-treat (ITT) effects were then 
estimated using linear regression (ANCOVA). The initial 
visual analogue scales for paranoia and for anxiety were 
both used as baseline covariates to increase precision.
Similar to the data reduction exercise for the paranoia 
measures, all of the 27 mediation variables were first 
entered into a PCA, resulting in 8 principal components 
with an eigenvalue greater than 1.0 (the well-known Kaiser 
criterion—explaining 30.1%, 9.2%, 7.2%, 6.1%, 5.5%, 
5.0%, 4.2%, and 3.9% of the total variation, respectively). 
These components were then subjected to an orthogonal 
(Varimax) rotation for ease of interpretation. The rotated 
components were then used as the mediators. The main 
variables contributing to these rotated components were: 
anomalous experiences, anxiety, worry, depression and 
negative beliefs about the self  (component 1); internal 
self-focus of attention (component 2); working memory 
(component 3); external focus of attention (component 
4); interpersonal sensitivity (component 5); belief flexibil-
ity and positive beliefs about self  and others (component 
6); threat anticipation (component 7); and catastrophizing 
and jumping to conclusions (component 8). Full details 
of the components are provided in supplementary table 
S1. Component scores were available for 114 participants.
Mediation was tested using regression methods follow-
ing the logic of Baron and Kenny.40 There were three steps 
to determine mediation: an ITT effect of randomization 
condition on the outcome (paranoia); an ITT effect of 
randomization condition on the putative mediator; and 
when the outcome (paranoia) is jointly predicted by both 
the randomization condition and mediator, the media-
tor effect is significant and the randomization condition 
effect is lowered. In these regressions, the binary dummy 
variables THC and Cognitive Awareness were entered 
together to test the effects of the randomization condi-
tions, and the initial visual analogue scales for paranoia 
and for anxiety were used as baseline covariates.
Acknowledging that we are primarily carrying out an 
exploratory analysis, we did not alter significance levels 
for multiple testing, agreeing with the view that “simply 
describing what tests of significance have been performed, 
and why, is generally the best method of dealing with 
multiple comparisons.”41 Data on all outcomes was avail-
able for 114 participants and with such small amounts of 
missing data, this is unlikely to be a cause of any signifi-
cant biases. All significance testing was two-tailed.
Results
The basic demographic data for the participant groups 
can be seen in table 1.
Paranoia
An ANCOVA with the paranoia principal component 
as the dependent variable, and controlling for baseline 
paranoia and anxiety levels, showed that THC signifi-
cantly increases paranoia, THC coefficient = 0.91, SE = 
0.43, t = 2.15, P = .034, and that the cognitive aware-
ness condition, if  it actually has any effects, may increase 
paranoia but not significantly, Cognitive Awareness coef-
ficient = 0.51, SE = 0.44, t = 1.16, P = .247 (see figure 2). 
Controlling for previous cannabis use did not affect the 
findings. (see supplementary table S2 for individual para-
noia outcome scores). Consistent with the analysis, there 
was a significant effect on self-reported psychotic symp-
toms as assessed by the CAPE (controlling for baseline 
anxiety and paranoia), THC coefficient = 4.20, SE = 
1.19, t = 3.54, P = .001, Cognitive Awareness coefficient 
= 1.02, SE = 1.23, t = 0.83, P = .407.
Effects on Mediators
ITT effects of the randomization condition on the media-
tion variables are reported in table 2. THC significantly 
increased scores on component 1 (anomalous experiences 
and negative affect) and decreased scores on component 
3 (working memory). The cognitive awareness condition 
decreased component 8 (catastrophizing and jumping to 
conclusions).
Mediation Analysis
Table 3 shows the results when the ITT effect for random-
ization condition on paranoia includes each mediator in 
turn. The key tests are for components 1 and 3, for which 
ITT effects on these mediators have been established. It 
can be seen that there is full mediation for component 
1 (anomalous experiences and negative affect), since the 
effect of THC on paranoia becomes nonsignificant but 
the effect of component 1 is highly significant. Consistent 
with this finding, there is little evidence of mediation by 
component 3 (working memory).
Discussion
Paranoia is a key psychotic experience, distributed as a 
quantitative trait in the population, which requires expla-
nation in its own right. This is the first experimental 
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Fig. 2. Composite scores for paranoia and the main mediator by randomization group.
Table 1. Composition of the Three Randomization Groups
Placebo THC THC + Awareness
(n = 41) (n = 41) (n = 39)
Mean age in years (SD) 30.3 (9.6) 30.8 (8.5) 28.0 (6.8)
Gender
 Male 30 26 25
 Female 11 15 14
Ethnicity
 White 38 36 37
 Black African 0 1 0
 Black other 0 0 1
 South Asian 0 1 1
 Other 3 3 0
Socioeconomic status
 Higher professional 2 5 0
 Lower professional 4 6 6
 Intermediate 5 5 4
 Own account workers 1 6 1
 Lower supervisory 4 1 4
 Semi-routine 6 3 4
 Routine 2 4 6
 Long-term unemployed 3 2 3
 Student 14 9 11
IQ (SD) 116.7 (10.8) 114.1 (12.9) 114.0 (11.5)
Number of times used cannabis in the past month (SD) 2.2 (5.8) 4.5 (12.7) 5.6 (17.3)
Paranoid Thoughts Scale Part B at screening (SD) 25.1 (10.6) 23.9 (9.4) 27.8 (11.6)
Note: THC, ∆9-tetrahydrocannabinol.
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study testing the causal effects of THC on paranoia spe-
cifically, and it also determined the mechanism of action, 
taking advantage of the 90-minute period for which the 
drug was active in participants. It included an extensive 
assessment battery of paranoia, using a real life social 
situation, an immersive virtual reality test, self-report 
questionnaires, and an interviewer assessment. The study 
clearly establishes that THC causes paranoia in vulner-
able individuals.
THC also led to the occurrence of anomalous experi-
ences, anxiety, worry, depression, and negative thoughts 
about the self. These factors—highly plausible candidates 
derived from a theoretical model—fully explained the 
increase in paranoia. This is evidence for their role in caus-
ing paranoia. The clear clinical implication is that reducing 
negative emotion in patients with delusions, eg, by reducing 
the tendency to worry, testing out anxious fears, and increas-
ing self-confidence, will lead to improvements in paranoia.4 
Also, the identification, normalization, and reduction of 
subtle anomalies of experience (eg, by reducing triggers and 
learning to tolerate the confusing sensory experiences) are 
clinically warranted. It is intriguing that negative affect and 
anomalous experience were so closely tied together. As in 
previous studies, THC also impaired working memory,14 but 
there was no evidence that changes in working memory were 
responsible for the occurrence of paranoia.
There is a note of caution: the validity of the media-
tion analysis is dependent on the assumption that an 
increase in component 1 (anomalous experiences, anxiety, 
worry, depression, and negative thoughts about the self) 
is the intermediate variable on the pathway from THC 
administration to increases in paranoia. The data cannot 
exclude the possibility that the change in paranoia leads 
to the change in component 1. However, if  we fit a regres-
sion model for component 1 with paranoia, experimental 
condition and baseline levels of paranoia and anxiety as 
covariates, we obtain a less parsimonious result. Although 
there is a highly significant effect of paranoia on compo-
nent 1 (estimated regression coefficient: +0.342 with SE = 
0.033; t = 10.46; P < .001), there remains an unexplained 
effect of THC that is not explained by paranoia (+0.355 
with SE = 0.152; t = 2.34; P = .021). We conclude from 
both a theoretical perspective and the relative simplicity 
of the first model that paranoia is likely to be the distal 
outcome.
By the inclusion of an awareness condition, the 
study also made the first experimental attempt to block 
Table 2. Intention-to-Treat Effects on the Mediators
Coefficient SE t P Value
Component 1 (Anomalous experiences and negative affect)
THC 0.62 0.21 2.95 .004**
Cognitive Awareness 0.14 0.22 0.66 .512
Component 2 (Self-focus)
THC 0.24 0.22 1.12 .267
Cognitive Awareness 0.10 0.23 0.43 .667
Component 3 (Working memory)
THC −0.49 0.21 −2.39 .019*
Cognitive Awareness −0.33 0.21 −1.55 .125
Component 4 (External attention)
THC 0.01 0.23 0.03 .974
Cognitive Awareness −0.15 0.23 −0.61 .544
Component 5 (Interpersonal sensitivity)
THC −0.40 0.22 −1.81 .073
Cognitive Awareness 0.15 0.23 0.63 .531
Component 6 (Belief  flexibility and positive beliefs)
THC 0.42 0.22 1.88 .063
Cognitive Awareness −0.42 0.22 −1.84 .069
Component 7 (Threat anticipation)
THC −0.17 0.23 −0.74 .459
Cognitive Awareness 0.08 0.24 0.35 .726
Component 8 (Catastrophizing and JTC)
THC 0.02 0.22 0.08 .935
Cognitive Awareness −0.59 0.23 −2.56 .012*
Note: JTC, jumping to conclusions; THC, ∆9-tetrahydrocannabinol. 
*P < .05, **P < .01.
Table 3. Effect on Paranoia of Randomization Condition and the 
Mediators Entered Together in Regression Analyses
Coefficient SE t P Value
THC −0.14 0.32 −0.43 .667
Cognitive Awareness 0.46 0.32 1.42 .158
Component 1 (Anomalous 
experiences and negative 
affect)
1.47 0.14 10.46 <.001***
THC 0.71 0.44 1.62 .109
Cognitive Awareness 0.64 0.45 1.42 .157
Component 2 (Self-focus) 0.26 0.19 1.34 .182
THC 0.76 0.45 1.68 .096
Cognitive Awareness 0.66 0.46 1.43 .155
Component 3 (Working 
memory)
−0.03 0.20 −0.14 .887
THC 0.77 0.43 1.78 .077
Cognitive Awareness 0.72 0.45 1.62 .109
Component 4 (External 
attention)
0.37 0.18 2.07 .041*
THC 0.89 0.44 2.02 .045*
Cognitive Awareness 0.63 0.45 1.39 .168
Component 5 (Interpersonal 
sensitivity)
0.30 0.19 1.60 .112
THC 0.79 0.45 1.76 .081
Cognitive Awareness 0.66 0.46 1.42 .160
Component 6 (Belief  flexibility 
and positive beliefs)
−0.03 0.19 −0.18 .858
THC 0.77 0.44 1.75 .084
Cognitive Awareness 0.67 0.46 1.47 .144
Component 7 (Threat 
anticipation)
−0.01 0.19 −0.06 .951
THC 0.77 0.44 1.75 .082
Cognitive Awareness 0.75 0.47 1.60 .112
Component 8 (Catastrophizing 
and JTC)
0.14 0.19 0.72 .472
Note: JTC, jumping to conclusions; THC, ∆9-tetrahydrocannabinol. 
*P < .05, ***P < .001.
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the misinterpretation considered central to paranoia. 
Contrary to prediction, this psychological manipulation 
did not decrease paranoia but perhaps had a paradoxical 
effect of exacerbating it, though statistical significance was 
not reached. The awareness condition may have increased 
sensitivity to paranoid thoughts. Interestingly, some par-
ticipants in this condition reported being aware that their 
suspiciousness was due to having had the cannabis, ie, 
awareness affected judgments of the cause of such fears. 
As one participant in the awareness condition put it: “I’m 
always a bit sensitive but this intensified totally because 
I’m full of cannabis.” The study indicates that misinter-
pretations in paranoia do not shift readily simply with 
provision of an alternative verbal explanation and that 
unintended consequences could arise from this approach.
The study could not address several issues. It is impos-
sible to rule out biases in the estimation of direct and 
indirect effects arising from hidden confounding. There 
would have been benefits for learning about the effects 
of the psychological manipulation by including an addi-
tional condition in which the cognitive awareness train-
ing was also provided with the placebo; however, adding 
further randomization conditions causes practical diffi-
culties since recruitment was labor intensive, with almost 
2000 people being screened for participation. Arguably, 
greater effects would have been observed by increasing 
the dose of THC, though attrition from side effects would 
have compromised data collection. The dose had ecologi-
cal validity since it is equivalent to about one strong can-
nabis cigarette. It would also have strengthened causal 
claims to have included randomization to other consti-
tutes of cannabis, such as cannabidiol,18 which may show 
opposite effects on the mechanisms underlying paranoia. 
The statistical strategy of PCA lessens the problem of 
multiple testing, which is a difficulty for the evaluation 
of multifactorial models, but does not provide results 
for individual assessments. The conclusions need to be 
validated by further experiments. As experiences such as 
paranoia begin to receive research attention in their own 
right, we expect to see the emergence of similar experi-
mental studies that determine the causes underlying indi-
vidual psychotic experiences.
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